Pulse Biosciences (NASDAQ:PLSE) Shares Up 8%

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price shot up 8% during trading on Thursday . The stock traded as high as $18.50 and last traded at $18.17. 48,116 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 216,777 shares. The stock had previously closed at $16.82.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Tuesday, August 6th.

Pulse Biosciences Stock Performance

The stock’s fifty day simple moving average is $14.39 and its two-hundred day simple moving average is $10.92. The stock has a market capitalization of $1.05 billion, a P/E ratio of -23.47 and a beta of 1.75.

Insider Buying and Selling

In related news, CEO Burke Thomas Barrett acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was acquired at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $85,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 71.50% of the stock is currently owned by insiders.

Institutional Trading of Pulse Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its holdings in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after purchasing an additional 1,608 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after buying an additional 2,952 shares during the period. Quest Partners LLC acquired a new position in Pulse Biosciences in the second quarter valued at $91,000. Bank of New York Mellon Corp lifted its holdings in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new stake in Pulse Biosciences during the first quarter valued at $88,000. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.